Pan-HDAC inhibitor LAQ824 inhibits the progression of pancreatic ductal adenocarcinoma and suppresses immune escape by promoting antigen presentation
- 31 March 2025
- journal article
- Published by Elsevier in International Immunopharmacology
- Vol. 154, 114528
Abstract
No abstract availableKeywords
Funding Information
- Capital Health Research and Development of Special Fund (Z201100005520090)
- National Key Research and Development Program of China
- National Key Research and Development Program of China Stem Cell and Translational Research (2021YFA1201102)
This publication has 59 references indexed in Scilit:
- The hallmarks of cancer immune evasionCancer Cell, 2024
- A membrane-associated MHC-I inhibitory axis for cancer immune evasionCell, 2023
- Pancreatic CancerJAMA, 2021
- An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in CancerCancer Cell, 2019
- MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case seriesCancer Immunology, Immunotherapy, 2019
- Trend of Histone Deacetylase Inhibitors in Cancer Therapy: Isoform Selectivity or Multitargeted StrategyMedicinal Research Reviews, 2014
- Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cellsBiochemical and Biophysical Research Communications, 2013
- DNA Damage-Mediated Induction of a Chemoresistant NicheCell, 2010
- Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cellsCancer Immunology, Immunotherapy, 2007
- Butyric acid, a potent inducer of erythroid differentiation in cultured erythroleukemic cellsCell, 1975